百洋以"产业投资人"身份打通医研成果转化全链条。 本文为IPO早知道原创 作者｜ 罗宾 微信公众号｜ipozaozhidao 据IPO早知道消息，3月29日，北京市自然科学基金联合基金集中签约仪式在中关村论坛重大成果专 场发布会上举行。 百洋医药与北京市科委中关村管委会、门头沟区政府签署战略合作协议，共同设 立"北京 市自然 科学基金—百洋医药创新联合基金"（下称"联合基金"），基金年度规模为5000万 元， 各方将携手推动基础研究与产业应用深度融合，加速优质科研成果落地转化。 北京市自然科学基金是北京市基础研究领域的重要资助渠道，致力于面向北京科技创新发展需求，支 持前沿探索与原始创新，推动基础研究与首都经济社会发展的深度融合。本次联合基金的设立，是落 实创新驱动发展战略、强化企业科技创新主体地位的深刻实践，也是发挥北京临床资源与科研人才优 势、服务北京国际科技创新中心建设的有力举措。 联合基金采用"企业出题、政府搭台、院所答题"的运行模式。 百洋医药立足产业端，深入临床场景 挖掘未满足的医疗需求，围绕临床转化与产业发展中的关键问题，提出研究命题。北京市自然科学基 金委员会统一组织项目申报与评审，将产业技术 ...

| 证券代码：301015 | 证券简称：百洋医药 | 公告编号：2026-008 | | --- | --- | --- | | 债券代码：123194 | 债券简称：百洋转债 | | 青岛百洋医药股份有限公司 关于对外投资暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、对外投资概述 （一）交易的基本情况 为拓展青岛百洋医药股份有限公司（以下简称"公司"或"百洋医药"）在 小核酸药物领域的布局，公司拟与思合基因（北京）生物科技有限公司（以下简 称"思合基因"）、北京市门头沟区百洋医药产业投资基金（有限合伙）（以下简 称"门头沟百洋基金"）等相关方签署《投资协议》，约定公司以现金方式向思合 基因投资 2,700 万元，投资后公司持有思合基因 10%股权。本次交易不会导致公 司合并报表范围变更。 （二）关联关系情况 思合基因现有股东门头沟百洋基金的执行事务合伙人为北京百洋众信康健 投资管理有限公司（以下简称"百洋众信"），百洋众信为公司控股股东百洋医药 集团有限公司（以下简称"百洋集团"）控制的公司，因此门头沟百洋基金为公 司的关联人。 门 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 青岛百洋医药股份有限公司（以下简称"公司"）第四届董事会第五次会议 于 2026 年 3 月 19 日以现场结合通讯的方式召开，会议通知已于 2026 年 3 月 13 日以邮件形式送达全体董事。本次会议由公司董事长付钢先生召集并主持，应出 席董事 9 人，实际出席董事 9 人，公司总经理、董事会秘书列席会议。本次会议 的召开符合有关法律、行政法规、部门规章、规范性文件和《公司章程》的规定， 会议决议合法、有效。 二、董事会会议审议情况 审议通过了《关于对外投资暨关联交易的议案》。 | 证券代码：301015 | 证券简称：百洋医药 | 公告编号：2026-007 | | --- | --- | --- | | 债券代码：123194 | 债券简称：百洋转债 | | 青岛百洋医药股份有限公司 第四届董事会第五次会议决议公告 特此公告。 1、第四届董事会第五次会议决议； 2、第四届董事会第四次独立董事专门会议决议。 青岛百洋医药股份有限公司 董事会 2026 年 3 月 19 日 为拓展公司 ...

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry as of March 16, 2026 [1] Core Insights - The report emphasizes the importance of products with price leadership amid rising costs in the supply chain due to geopolitical tensions and policy changes affecting raw material prices [2] - The report highlights the significant price increases in pharmaceutical raw materials, particularly vitamins and amino acids, which have seen price increases of 40.54% and 84.66% respectively since the beginning of the year [2] - The report notes the approval of China's first invasive brain-machine interface, marking a significant milestone in the medical device sector [5] - The report indicates a strong trend in China's innovative pharmaceuticals going global, with a notable increase in licensing-out transactions [6] Summary by Sections 1. Supply Chain Dynamics - The report discusses the impact of rising prices in upstream chemical products on pharmaceutical raw materials, stressing that the ability to pass on these costs is crucial for maintaining profitability [2] - It mentions that 90% of monitored products have seen price increases, with the chemical product price index rising by 28.52% since the beginning of the year [2] 2. Market Trends in Disposable Gloves - The report details the price increases in disposable nitrile gloves and PVC gloves due to rising costs of raw materials like butadiene and acrylonitrile, which have increased by 84.43% and 47.30% respectively [3] - It notes that the domestic utilization rate for nitrile gloves has improved, and export prices have been rising since late 2025 [3] 3. Regulatory Environment - The report highlights the impact of dual-use item management on the pricing of key materials, creating significant price disparities between domestic and international markets [4] - It suggests that stricter controls on resources like rare earths could enhance the competitive advantage of domestic medical products [4] 4. Innovations in Medical Devices - The report discusses the approval of the brain-machine interface by the National Medical Products Administration, which is expected to open new market opportunities [5] - It outlines the potential for significant market growth in this area, given the high number of spinal cord injury patients in China [5] 5. International Expansion of Chinese Pharmaceuticals - The report notes that there have been 39 licensing-out transactions in the innovative drug sector, with upfront payments totaling approximately $2.953 billion [6] - It emphasizes that the trend of Chinese pharmaceuticals going global continues to strengthen, with a focus on small nucleic acid drugs and dual antibodies [7] 6. Stock Recommendations - The report recommends focusing on raw material suppliers with price leadership, such as Zhejiang Medicine and Chuan Ning Biological, and highlights companies like Inco Medical and Blue Sail Medical in the disposable glove sector [8] - It also suggests monitoring companies involved in the invasive brain-machine interface and small nucleic acid drugs, indicating potential for growth in these areas [8]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of March 16, 2026 [1] Core Insights - The report emphasizes the importance of price leadership in the pharmaceutical sector, particularly in the context of rising raw material costs due to geopolitical tensions and supply chain disruptions [2] - The report highlights the approval of China's first invasive brain-machine interface, marking a significant milestone in medical technology and potential market opportunities [5] - The report notes a strong trend in China's innovative drug exports, with a significant increase in licensing deals and collaborations, indicating robust growth in the sector [6] Summary by Sections Supply Chain and Pricing Dynamics - The report discusses the impact of macroeconomic changes on supply chains, particularly the price increases in upstream chemical products affecting pharmaceutical raw materials [2] - It mentions that 90% of monitored products saw price increases, with the chemical product price index rising by 28.52% since the beginning of the year [2] - Specific raw materials like Vitamin E and methionine have seen price increases of 40.54% and 84.66% respectively since the start of the year [2] Market Trends and Innovations - The report details the rising prices of disposable gloves due to increased costs of upstream materials, with notable price hikes in butadiene and acrylonitrile [3] - It highlights the competitive landscape for disposable gloves, noting that leading companies are leveraging their cost advantages to implement price increases [3] - The report also discusses the potential for domestic medical products to benefit from export controls on dual-use items, enhancing China's competitive edge [4] Regulatory Developments and Market Opportunities - The approval of the brain-machine interface by the National Medical Products Administration is a significant development, with a large potential patient base in China [5] - The report outlines the introduction of new pricing guidelines for invasive brain-machine interfaces, which could facilitate market entry and reimbursement [5] Investment Recommendations - The report recommends focusing on raw material producers with price leadership, such as Zhejiang Medicine and Chuan Ning Biological, and highlights companies like Yingke Medical and Blue Sail Medical in the disposable glove sector [8] - It suggests monitoring companies benefiting from resource management policies, such as Aidi Te, and those involved in the invasive brain-machine interface market, like Meihua Medical [8] - The report also emphasizes the growth potential in the small nucleic acid drug sector, recommending companies like Yuyuan Pharmaceutical and Sunshine Nuohe [8] Company Performance and Forecasts - The report provides earnings forecasts for key companies, indicating a positive outlook for several firms in the pharmaceutical sector, with specific EPS and PE ratios highlighted for investment consideration [9]

| 证券代码: | 301015 | | --- | --- | | 债券代码: | 123194 | 证券代码：301015 证券简称：百洋医药 公告编号：2026-006 债券代码：123194 债券简称：百洋转债 青岛百洋医药股份有限公司 | 北京百洋诚 创医药研发 | 20,000, | | 9,980,0 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 000 | 3.81% | 00 | 9,980,000 | 49.90% | 1.90% | 0 | 0.00% | 0 | 0.00% | | 有限公司 | | | | | | | | | | | | 天津晖桐资 | | | | | | | | | | | | 产管理合伙 | 5,730,7 | 1.09% | 2,800,0 | 2,800,000 | 48.86% | 0.53% | 0 | 0.00% | 0 | 0.00% | | 企业（有限 | 50 | | 00 | | | | | | | | | 合伙） | ...

| 证券代码：301015 | 证券简称：百洋医药 | 公告编号：2026-005 | | --- | --- | --- | | 债券代码：123194 | 债券简称：百洋转债 | | | | 是否为控 股股东或 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | | 本次解除 | 占其所 | 占公司 | 质押 | 质押 | | | 名称 | 第一大股 | 质押数量 | 持股份 | 总股本 | 起始日 | 解除日 | 质权人 | | | 东及其一 | （股） | 比例 | 比例 | | | | | | 致行动人 | | | | | | | | 百洋医药集团 | 是 | 6,040,000 | 1.71% | 1.15% | 2025 年 5 月 | 2026 年 3 | 西藏信托有限 | | 有限公司 | | | | | 22 日 | 月 9 日 | 公司 | | 合计 | | 6,040,000 | 1.71% | 1.15% | - | - | - | 青岛百洋医药股份有限公司 关于控股股东部分股份解除质押的公告 ...

| 证券代码：301015 | 证券简称：百洋医药 | 公告编号：2026-004 | | --- | --- | --- | | 债券代码：123194 | 债券简称：百洋转债 | | 青岛百洋医药股份有限公司 关于变更持续督导保荐代表人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 青岛百洋医药股份有限公司（以下简称"公司"）于近日收到保荐机构东兴 证券股份有限公司（以下简称"东兴证券"）出具的《关于更换持续督导保荐代 表人的函》。 东兴证券作为公司 2021 年度首次公开发行股票并在创业板上市项目和 2023 年度向不特定对象发行可转换公司债券项目的持续督导保荐机构，目前正在履行 持续督导职责。东兴证券委派朱海洲先生、姚维先生作为公司保荐代表人，负责 上述项目的持续督导工作，持续督导期限至募集资金使用完毕为止。 本次变更后，公司持续督导保荐代表人为朱海洲先生、毕文国先生，持续督 导期至中国证券监督管理委员会和深圳证券交易所规定的持续督导义务结束为 止。 公司董事会对姚维先生在公司持续督导期间所做的工作表示衷心感谢！ 特此公告。 青岛百洋医药股份有 ...

Core Viewpoint - Baiyang Pharmaceutical's stock price experienced a 3.46% increase on February 24, closing at 24.21 yuan, with a trading volume of 229 million yuan and a turnover rate of 1.78% [1] Recent Events - On February 24, Baiyang Pharmaceutical recorded a financing purchase of 30.30 million yuan, with a net financing purchase of 4.35 million yuan, bringing the financing balance to 484 million yuan, which accounts for 3.81% of the circulating market value, a relatively high level over the past year [1] - The company's margin balance was low at 450,300 yuan, indicating limited short-selling activity [1] - There have been no other significant announcements or operational events from the company recently [1]

Group 1 - The core viewpoint of the article is that Baiyang Pharmaceutical has announced that its subsidiary, Baiyang Pharmaceutical, has received proposed selection qualifications for several drugs, which are expected to be implemented by the end of March 2026 [2] - The drugs that received proposed selection qualifications include: Nait (Nifedipine Controlled-Release Tablets), Naqi (Celecoxib Capsules), Naishu (Duloxetine Hydrochloride Enteric-Coated Capsules), and Naixin (Memantine Hydrochloride Sustained-Release Capsules) [2] - Currently, these drugs account for a small proportion of the company's revenue [2]